JP Morgan Chase’s CRISPR Therapeutics CRSP Stock Holding History

JP Morgan Chase’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,000	Closed	-$1.42M	–	7790
2026 Q1	$1.42M	Sell	32,000 -21,200	-40%	-$1.12M	﹤0.01%	4355
2025 Q4	$2.79M	Buy	+53,200	New	+$3.19M	﹤0.01%	3838
2025 Q3	–	Sell	-10,300	Closed	-$501K	–	7443
2025 Q2	$501K	Buy	+10,300	New	+$399K	﹤0.01%	4784
2024 Q2	–	Sell	-30,000	Closed	-$2.04M	–	7405
2024 Q1	$2.04M	Sell	30,000 -170,000	-85%	-$12.2M	﹤0.01%	3828
2023 Q4	$12.5M	Buy	+200,000	New	+$11.1M	﹤0.01%	2247
2019 Q1	–	Sell	-55,000	Closed	-$1.57M	–	5792
2018 Q4	$1.57M	Sell	55,000 -2,000	-4%	-$69.5K	﹤0.01%	3452
2018 Q3	$2.53M	Buy	57,000 +7,000	+14%	+$367K	﹤0.01%	3297
2018 Q2	$2.94M	Buy	+50,000	New	+$2.85M	﹤0.01%	3111

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's CRSP Position: Q2 2026 in Review

JP Morgan Chase reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q2 2026, selling an estimated $1.37M and leaving 431,669 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

JP Morgan Chase first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $92.8M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

JP Morgan Chase held 431,669 shares of CRISPR Therapeutics worth $24.6M as of Q2 2026.
JP Morgan Chase sold 25,970 CRISPR Therapeutics shares in Q2 2026, an estimated $1.37M.
CRISPR Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2040 holding.
JP Morgan Chase first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
JP Morgan Chase's CRISPR Therapeutics position peaked at $92.8M in Q2 2021.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.